Cited by 104Cardiovascular Disease and AdiposityAdipose Tissue and MetabolismAdipokines, Inflammation, and Metabolic Diseases

Epicardial fat: a new cardiovascular therapeutic target

Iacobellis, Gianluca·2016·Current Opinion in Pharmacology

Abstract

Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2016.01.004

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 41 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Iacobellis, G.
Affiliations
University of Miami (US)
Corresponding author
Iacobellis, Gianluca
Venue
Current Opinion in Pharmacology
Publisher
Elsevier BV
Published
2016-04
Volume
27
Pages
13-18
ISSN
1471-4892 (ISSN-L)
OpenAlex
W2262304120
Cited by
104
References
41
Citations by year
2026: 8 · 2025: 5 · 2024: 10 · 2023: 10 · 2022: 11 · 2021: 6 · 2020: 15 · 2019: 12 · 2018: 10 · 2017: 10 · 2016: 7
FWCI
2.27
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
epicardial adipose tissue, visceral adipose tissue, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, statins, energy expenditure, cardiometabolic disease, adipose tissue metabolism
MeSH terms
Adipose Tissue, Animals, Cardiovascular Agents, Cardiovascular Diseases, Cardiovascular System, Fats, Humans, Pericardium, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review